PT - JOURNAL ARTICLE AU - Mattia Allieta AU - Andrea Allieta AU - Davide Rossi Sebastiano TI - COVID-19 outbreak in Italy: estimation of reproduction numbers over two months toward the Phase 2 AID - 10.1101/2020.05.12.20076794 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.12.20076794 4099 - http://medrxiv.org/content/early/2020/05/18/2020.05.12.20076794.short 4100 - http://medrxiv.org/content/early/2020/05/18/2020.05.12.20076794.full AB - After two months from the first case in COVID-19 outbreak, Italy counts more than 190,000 confirmed positive cases. From the beginning of April 2020, the nationwide lockdown started to show early effects by reducing the total cumulative incidence reached by the epidemic wave. This allows the government to program the measures to loosen lockdown restrictions for the so called “Phase 2”. Here we provided the reproduction number estimation both in space and in time from February 24th to April 24th, 2020 across two months into the epidemic. Our estimates suggest basic reproduction number averaged over all the regions of 3.29, confirming that epidemiological figures of the SARS-CoV-2 epidemic in Italy are higher than those observed at the early stage of Wuhan (China) outbreak. Based on the SARS-CoV-2 transmission dynamics reported here, we gave a quantitative evaluation of the efficiency of the government measures to low the reproduction number under the unity (control regime). We estimated that among the worst hit regions in Italy, Lombardy reached the control regime on March 22nd followed by Emilia-Romagna (March 23th), Veneto (March 25th) and Piemonte (March 26th). Overall, we found that the mean value of time to reach the control regime in all the country is about 31 days from the February 24th and about 14 days from the first day of nationwide lockdown (March 12th). Finally, we highlighted the interplay between the reproduction number and two demographic indices in order to probe the “state of activity” of the epidemic for each Italian region in the control regime. We believe that this approach can provide a tool in the management of “Phase 2”, potentially helping in challenging decision to continue, ease or tighten up restrictions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings were derived from the following resources available in the public domain: https://github.com/pcm-dpc/COVID-19 http://dati.istat.it/Index.aspx?QueryId=18460 https://github.com/pcm-dpc/COVID-19 http://dati.istat.it/Index.aspx?QueryId=18460